India, Nov. 12 -- Lakefront Biotherapeutics NV (LKFT) Wednesday reported profit for the 9-month period from loss last year, supported by lower costs and financial gains.
Company Profile
Lakefront, formerly Galapagos, develops medicines for autoimmune and inflammatory diseases.
Nine-Month 2026 Financial Results
Net profit totaled €13.93 million, or €0.21 per share, compared to €461.26 million loss, or €7.00 per share, a year earlier.
The company recorded profit of €7.54 million, or €0.12 per share from continuing operations for the first nine months of 2026, while in the corresponding year Lakefront incurred a loss of €463 million, or €7.03 per share.
Total revenue fell to €26.17 mi...